Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Informa and Relx top-and-tail FTSE 100

Thu, 10th Feb 2022 09:01

(Alliance News) - Stock prices in London opened mostly higher on Thursday on a busy day for company earnings, with Informa, Relx and Unilever all announcing share buybacks.

The FTSE 100 index was up 20.62 points, or 0.3%, at 7,664.04 early Thursday. The mid-cap FTSE 250 index was up 70.87 points, or 0.3%, at 22,254.88. The AIM All-Share index was down 2.91 points, 0.2%, at 1,092.15.

The Cboe UK 100 index was up 0.3% at 760.85. The Cboe 250 was up 0.4% at 19,910.08, but the Cboe Small Companies was 0.2% lower at 15,561.02.

In mainland Europe, the CAC 40 stock index in Paris was up 0.1% and the DAX 40 in Frankfurt was 0.3% higher.

In the FTSE 100, Informa was the best performer, up 4.0%, after the business information and events organiser said it will launch a share buyback and said it saw a strong performance through 2021.

In addition, Informa agreed to sell Pharma Intelligence, the largest business within its Informa Intelligence division, to private equity firm Warburg Pincus for GBP1.9 billion.

The buyback programme will commence with immediate effect and run through to the AGM in June. The maximum amount allocated to the initial tranche of the buyback programme will be GBP100 million, Informa said.

Ahead of its annual results on March 15, Informa said it expects to report trading in 2021 was in line with guidance of GBP1.8 billion in revenue and GBP375 million in adjusted operating profit. The company posted revenue of GBP1.6 billion and adjusted operating profit of GBP267.8 million in 2020.

AstraZeneca was up 3.0%. The drugmaker reported a rise in annual revenue which it attributed to its pipeline and commercial delivery, alongside an accelerated strategic transformation through the acquisition of Alexion Pharmaceuticals.

For 2021, revenue rose to USD37.42 billion from USD26.62 billion in 2020. Looking ahead, for 2022 AstraZeneca guided at constant exchange rates for a high-teens percentage increase in total revenue and a mid-to-high twenties percentage increase in core earnings per share.

Prudential was up 2.5%. The insurer said Chief Executive Officer Mike Wells intends to retire from his role at the insurer at the end of March 2022 and will not stand for re-election as a director at the next annual general meeting.

Prudential said it is conducting a search for a CEO to be based in Asia to succeed Wells, which includes both internal and external candidates. Wells became CEO in 2015, having first joined the insurer in 1995.

Mark FitzPatrick, currently CFO and COO, will become interim CEO when Wells steps down. FitzPatrick has asked the board not to consider him for the permanent CEO role, the company said.

At the other end of the large-caps, Relx was the worst performer, down 4.0%, after the data analytics provider's earnings missed market forecasts.

For 2021, Relx generated revenue of GBP7.24 billion, up from GBP7.11 billion in 2020. However, the figure missed consensus estimates of GBP7.34 billion. Pretax profit was GBP1.80 billion, up from GBP1.48 billion in 2020, but was below forecasts of GBP2.1 billion.

Relx raised its annual dividend by 6.0% to 49.8 pence from 47.0p the year before and said it will launch a GBP500 million share buyback in 2022.

Looking ahead, the Anglo-Dutch firm expects 2022 full year underlying growth rates in revenue and adjusted operating profit, as well as constant currency growth in adjusted earnings per share, to remain above historical trends.

Unilever was down 1.5% as the consumer goods firm promised to make no major acquisition in the "foreseeable future" after its failed tilt at the GSK Consumer Healthcare business.

The Dove soap maker also reported annual results and launched a share buyback programme of up to EUR3 billion over the next two years.

For 2021, Unilever generated revenue of EUR52.44 billion, up from EUR50.72 billion in 2020. The figure was higher than the company-compiled consensus forecast of EUR52.11 billion. Pretax profit rose to EUR8.6 billion from EUR8.0 billion the year prior.

Underlying pretax profit was EUR9.6 billion, up from EUR9.4 billion in 2020. Underlying sales growth was 4.5% in 2021, beating the consensus estimate of 4.3%.

Looking ahead, Unilever expects underlying sales growth in 2022 in the range of 4.5% to 6.5%. It also expects high input cost inflation in the first half of over EUR2 billion. This may moderate in the second half to around EUR1.5 billion, it noted.

Chris Beckett, head of equity research at Quilter Cheviot, commented: "What really matters is the margin guidance for 2022, which is down 140-240 basis points, along with investment in marketing, research & development and capex. Margins are expected to recover in 2023/24, but will the market let them get away with it? Most likely, no.

"Along with the amended margin guidance, there are serious investor concerns around the lack of management credibility, as demonstrated by investor reaction to the failed GSK bid. Management have shown they are unable to consistently grow both sales and margins and have ruled out any significant acquisitions for now."

In the FTSE 250, Darktrace was the best performer, up 3.5%, after the cybersecurity provider said it signed a "million-dollar deal" with an unnamed global electronics corporation.

In Tokyo, the Nikkei 225 index closed up 0.4% on Thursday. In China, the Shanghai Composite ended up 0.2%, while the Hang Seng index in Hong Kong was up 0.1%. The S&P/ASX 200 in Sydney closed up 0.3%.

The dollar was higher across the board. The pound was quoted at USD1.3547 early Thursday in London, down from USD1.3551 at the London equities close Wednesday.

The euro was priced at USD1.1426, down from USD1.1437. Against the Japanese yen, the dollar was trading at JPY115.63, up from JPY115.44.

Brent oil was quoted at USD91.23 a barrel Thursday morning, down from USD91.90 late Wednesday. Gold stood at USD1,835.80 an ounce, higher against USD1,830.69.

Thursday's economic calendar has the US consumer price index for January and weekly jobless claims at 1330 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.